Stomach cancer falls into three broad subtypes that respond differently to currently available therapies.
Using a technology called microarray-based gene expression profiling, researchers analyzed 248 gastric tumors, then further grouped them according to the genes that were expressed in the tumors. The gene expression analysis broadly sorts the tumors into three subtypes: proliferative, metabolic and mesenchymal. These subtypes also differ in their genomic and epigenomic properties. [Read Article]
For more information:
[1] Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, et al. Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. Gastroenterology. 2013 Sep;145(3):554-65. doi: 10.1053/j.gastro.2013.05.010. Epub 2013 May 14.[Article][PubMed]
[2] NCT01231399 – Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
Illustration Courtesy: Duke Medicine.
Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
